{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:06:31Z","timestamp":1757703991282,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Leber Hereditary Optic Neuropathy (LHON) is a rare, maternally-inherited mitochondrial disease that primarily affects retinal ganglion cells (RGCs) and their axons in the optic nerve, leading to irreversible, bilateral severe vision loss. Lenadogene nolparvovec gene therapy was developed as a treatment for patients with vision loss from LHON caused by the most prevalent m.11778G\u2009&gt;\u2009A mitochondrial DNA point mutation in the <jats:italic>MT-ND4<\/jats:italic> gene. Lenadogene nolparvovec is a replication-defective recombinant adeno-associated virus vector 2 serotype 2 (AAV2\/2), encoding the human wild-type MT-ND4 protein. Lenadogene nolparvovec was administered by intravitreal injection (IVT) in LHON patients harboring the m.11778G\u2009&gt;\u2009A ND4 mutation in a clinical development program including one phase 1\/2 study (REVEAL), three phase 3 pivotal studies (REVERSE, RESCUE, REFLECT), and one long-term follow-up study (RESTORE, the follow-up of REVERSE and RESCUE patients).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 67-year-old woman with <jats:italic>MT-ND4<\/jats:italic> LHON, included in the REVERSE clinical study, received a unilateral IVT of lenadogene nolparvovec in the right eye and a sham injection in the left eye in May 2016, 11.4\u2009months and 8.8\u2009months after vision loss in her right and left eyes, respectively. The patient had a normal brain magnetic resonance imaging with contrast at the time of diagnosis of LHON. Two years after treatment administration, BCVA had improved in both eyes. The product was well tolerated with mild and resolutive anterior chamber inflammation in the treated eye. In May 2019, the patient was diagnosed with a right temporal lobe glioblastoma, IDH-wildtype, World Health Organization grade 4, based on histological analysis of a tumor excision. The brain tumor was assessed for the presence of vector DNA by using a sensitive validated qPCR assay targeting the ND4 sequence of the vector.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>ND4 DNA was not detected (below 15.625 copies\/\u03bcg of genomic DNA) in DNA extracted from the brain tumor, while a housekeeping gene DNA was detected at high levels. Taken together, this data shows the absence of detection of lenadogene nolparvovec in a brain tumor (glioblastoma) of a treated patient in the REVERSE clinical trial 3 years after gene therapy administration, supporting the long-term favorable safety of lenadogene nolparvovec.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-022-02787-y","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T13:11:02Z","timestamp":1657631462000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Absence of lenadogene nolparvovec DNA in a brain tumor biopsy from a patient in the REVERSE clinical study, a case report"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4898-7839","authenticated-orcid":false,"given":"Nancy J.","family":"Newman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Schniederjan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pia R.","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Calkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Yu-Wai-Man","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Biousse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerio","family":"Carelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magali","family":"Taiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois","family":"Rugiero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pramila","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Rogue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9-Alain","family":"Sahel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Ancian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,12]]},"reference":[{"issue":"4","key":"2787_CR1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/WNO.0000000000000570","volume":"37","author":"V Carelli","year":"2017","unstructured":"Carelli V, Carbonelli M, de Coo IF, Kawasaki A, Klopstock T, Lagr\u00e8ze WA, et al. International consensus statement on the clinical and therapeutic Management of Leber Hereditary Optic Neuropathy. J Neuroophthalmol. 2017;37(4):371\u201381. https:\/\/doi.org\/10.1097\/WNO.0000000000000570.","journal-title":"J Neuroophthalmol"},{"key":"2787_CR2","doi-asserted-by":"publisher","unstructured":"Newman NJ, Carelli V, Taiel M, Yu-Wai-Man P. Visual outcomes in Leber hereditary optic neuropathy patients with the m.11778G.A (MTND4) mitochondrial DNA mutation. J Neuroophthalmol. 2020. https:\/\/doi.org\/10.1097\/WNO.0000000000001045.","DOI":"10.1097\/WNO.0000000000001045"},{"key":"2787_CR3","doi-asserted-by":"publisher","unstructured":"Yu-Wai-Man P, Newman NJ, Carelli V, La Morgia C, Biousse V, Bandello FM, et al. Taiel M and Sahel J-A, for the LHON REALITY study group. Natural history of patients with Leber hereditary optic neuropathy\u2014results from the REALITY study. Eye (Lond). 2021. https:\/\/doi.org\/10.1038\/s41433-021-01535-9.","DOI":"10.1038\/s41433-021-01535-9"},{"key":"2787_CR4","doi-asserted-by":"publisher","unstructured":"Bonnet C, AugustinS ES, B\u00e9nit P, Bouaita A, Rustin P, Sahel J-A, et al. The optimized allotopic expression of ND1 or ND4 genes restores respiratory chain complex I activity in fibroblasts harboring mutations in these genes. Biochim Biophys Acta. 2008. https:\/\/doi.org\/10.1016\/j.bbamcr.2008.04.018.","DOI":"10.1016\/j.bbamcr.2008.04.018"},{"key":"2787_CR5","doi-asserted-by":"publisher","unstructured":"Cwerman-Thibault H, Augustin S, Lechauve C, Ayache J, Ellouze S, Sahel J-A, et al. Nuclear expression of mitochondrial ND4 leads to the protein assembling in complex I and prevents optic atrophy and visual loss. Mol Ther Methods Clin Dev. 2015. https:\/\/doi.org\/10.1038\/mtm.2015.3.","DOI":"10.1038\/mtm.2015.3"},{"key":"2787_CR6","doi-asserted-by":"publisher","unstructured":"Bonnet C, Kaltimbacher V, Ellouze S, Augustin S, B\u00e9nit P, Forster V, et al. Allotopic mRNA localization to the mitochondrial surface rescues respiratory chain defects in fibroblasts harboring mitochondrial DNA mutations affecting complex I or v subunits. Rejuvenation Res. 2007. https:\/\/doi.org\/10.1089\/rej.2006.0526.","DOI":"10.1089\/rej.2006.0526"},{"key":"2787_CR7","doi-asserted-by":"publisher","unstructured":"Gray RE, Law RH, Devenish RJ, Nagley P. Allotopic expression of mitochondrial ATP: synthase genes in nucleus of Saccharomyces cerevisiae. Methods Enzymol. 1996. https:\/\/doi.org\/10.1016\/s0076-6879(96)64035-x.","DOI":"10.1016\/s0076-6879(96)64035-x"},{"key":"2787_CR8","doi-asserted-by":"publisher","unstructured":"Guy J, Qi X, Pallott F, Schon EA, Manfredi G, Carelli V, et al. Rescue of a mitochondrial deficiency causing Leber hereditary optic neuropathy. Ann Neurol. 2002. https:\/\/doi.org\/10.1002\/ana.10354.","DOI":"10.1002\/ana.10354"},{"key":"2787_CR9","doi-asserted-by":"publisher","unstructured":"Koilkonda RD, Chou TH, Porciatti V, Hauswirth WW, Guy J. Induction of rapid and highly efficient expression of the human ND4 complex I subunit in the mouse visual system by self-complementary adeno-associated virus. Arch Ophthalmol. 2010. https:\/\/doi.org\/10.1001\/archophthalmol.2010.135.","DOI":"10.1001\/archophthalmol.2010.135"},{"key":"2787_CR10","doi-asserted-by":"publisher","unstructured":"Koilkonda R, Yu H, Talla V, Porciatti V, Feuer WJ, Hauswirth WW, et al. LHON gene therapy vector prevents visual loss and optic neuropathy induced by G11778A mutant mitochondrial DNA: biodistribution and toxicology profile. Invest Ophthalmol Vis Sci. 2014. https:\/\/doi.org\/10.1167\/iovs.14-15388.","DOI":"10.1167\/iovs.14-15388"},{"key":"2787_CR11","doi-asserted-by":"publisher","unstructured":"Vignal-Clermont C, Girmens JF, Audo I, Said SM, Errera MH, Plaine L, et al. Safety of intravitreal gene therapy for treatment of subjects with Leber hereditary optic neuropathy due to mutations in the mitochondrial ND4 gene: the REVEAL study. BioDrugs. 2021. https:\/\/doi.org\/10.1007\/s40259-021-00468-9.","DOI":"10.1007\/s40259-021-00468-9"},{"key":"2787_CR12","doi-asserted-by":"publisher","unstructured":"Yu-Wai-Man P, Newman NJ, Carelli V, Moster ML, Biousse V, Sadun AA, et al. Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy. Sci Transl Med. 2020. https:\/\/doi.org\/10.1126\/scitranslmed.aaz7423.","DOI":"10.1126\/scitranslmed.aaz7423"},{"key":"2787_CR13","doi-asserted-by":"publisher","unstructured":"Newman NJ, Yu-Wai-Man P, Carelli V, Moster ML, Biousse V, Vignal-Clermont C, et al. LHON study group. Efficacy and safety of intravitreal gene therapy for Leber hereditary optic neuropathy treated within 6 months of disease onset. Ophthalmology. 2021. https:\/\/doi.org\/10.1016\/j.ophtha.2020.12.012.","DOI":"10.1016\/j.ophtha.2020.12.012"},{"key":"2787_CR14","doi-asserted-by":"publisher","unstructured":"Calkins DJ, Yu-Wai-Man P, Newman NJ, Biousse V, Taiel M, Singh P, et al. Biodistribution of intravitreal enadogene nolparvovec gene therapy in non-human Primates. Mol Ther - Methods Clin Dev. 2021. https:\/\/doi.org\/10.1016\/j.omtm.2021.09.013.","DOI":"10.1016\/j.omtm.2021.09.013"},{"key":"2787_CR15","doi-asserted-by":"publisher","unstructured":"Rizzo S, Belting C, Cinelli L, Allegrini L. Visual field changes following implantation of the Argus II retinal prosthesis. Graefes Arch Clin Exp Ophthalmol. 2015. https:\/\/doi.org\/10.1007\/s00417-014-2822-0.","DOI":"10.1007\/s00417-014-2822-0"},{"key":"2787_CR16","doi-asserted-by":"publisher","unstructured":"Seitz IP, Michalakis S, Wilhelm B, Reichel FF, Ochakovski GA, Zrenner E, et al. Superior retinal gene transfer and biodistribution profile of subretinal versus intravitreal delivery of AAV8 in nonhuman Primates. Invest Ophthalmol Vis Sci. 2017. https:\/\/doi.org\/10.1167\/iovs.17-22473.","DOI":"10.1167\/iovs.17-22473"},{"key":"2787_CR17","doi-asserted-by":"publisher","unstructured":"Klein RL, Muir D, King MA, Peel AL, Zolotukhin S, M\u00f6ller JC, et al. Long-term actions of vector-derived nerve growth factor or brain-derived neurotrophic factor on choline acetyltransferase and Trk receptor levels in the adult rat basal forebrain. Neuroscience. 1999. https:\/\/doi.org\/10.1016\/s0306-4522(98)00537-5.","DOI":"10.1016\/s0306-4522(98)00537-5"},{"key":"2787_CR18","doi-asserted-by":"publisher","unstructured":"Rivera VM, Gao GP, Grant RL, Schnell MA, Zoltick PW, Rozamus LW, et al. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood. 2005. https:\/\/doi.org\/10.1182\/blood-2004-06-2501.","DOI":"10.1182\/blood-2004-06-2501"},{"key":"2787_CR19","doi-asserted-by":"publisher","unstructured":"Niemeyer GP, Herzog RW, Mount J, Arruda VR, Tillson DM, Hathcock J, et al. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood. 2009. https:\/\/doi.org\/10.1182\/blood-2008-10-181479.","DOI":"10.1182\/blood-2008-10-181479"},{"key":"2787_CR20","doi-asserted-by":"publisher","unstructured":"Stieger K, Schroeder J, Provost N, Mendes-Madeira A, Belbellaa B, Le Meur G, et al. Detection of intact rAAV particles up to 6 years after successful gene transfer in the retina of dogs and primates. Mol Ther. 2009. https:\/\/doi.org\/10.1038\/mt.2008.283.","DOI":"10.1038\/mt.2008.283"},{"key":"2787_CR21","doi-asserted-by":"publisher","unstructured":"Chu Y, Bartus RT, Manfredsson FP, Olanow CW, Kordower JH. Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease. Brain. 2020. https:\/\/doi.org\/10.1093\/brain\/awaa020.","DOI":"10.1093\/brain\/awaa020"},{"key":"2787_CR22","doi-asserted-by":"publisher","unstructured":"Leone P, Shera D, McPhee SW, Francis JS, Kolodny EH, Bilaniuk LT, et al. Long-term follow-up after gene therapy for Canavan disease. Sci Transl Med. 2012. https:\/\/doi.org\/10.1126\/scitranslmed.3003454.","DOI":"10.1126\/scitranslmed.3003454"},{"key":"2787_CR23","doi-asserted-by":"publisher","unstructured":"Guy J, Feuer WJ, Davis JL, Porciatti V, Gonzalez PJ, Koilkonda RD, et al. Gene therapy for Leber hereditary optic neuropathy: low- and medium-dose visual results. Ophthalmology. 2017. https:\/\/doi.org\/10.1016\/j.ophtha.2017.05.016.","DOI":"10.1016\/j.ophtha.2017.05.016"},{"key":"2787_CR24","doi-asserted-by":"publisher","unstructured":"Yang S, Ma S-Q, Wan X, He H, Pei H, Zhao M-J, et al. Long-term outcomes of gene therapy for the treatment of Leber's hereditary optic neuropathy. EBioMedicine. 2016. https:\/\/doi.org\/10.1016\/j.ebiom.2016.07.002.","DOI":"10.1016\/j.ebiom.2016.07.002"},{"key":"2787_CR25","doi-asserted-by":"publisher","unstructured":"Yuan J, Zhang Y, Liu H, Wang D, Du Y, Tian Z, et al. Seven-year follow-up of gene therapy for Leber's hereditary optic neuropathy. Ophthalmology. 2020. https:\/\/doi.org\/10.1016\/j.ophtha.2020.02.023.","DOI":"10.1016\/j.ophtha.2020.02.023"},{"key":"2787_CR26","doi-asserted-by":"publisher","unstructured":"Bucher K, Rodr\u00edguez-Bocanegra E, Dauletbekov D, Fischer MD. Immune responses to retinal gene therapy using adeno-associated viral vectors - implications for treatment success and safety. Prog Retin Eye Res. 2020. https:\/\/doi.org\/10.1016\/j.preteyeres.2020.100915.","DOI":"10.1016\/j.preteyeres.2020.100915"},{"key":"2787_CR27","doi-asserted-by":"publisher","unstructured":"Chiha W, Bartlett CA, Petratos S, Fitzgerald M, Harvey AR. Intravitreal application of AAV-BDNF or mutant AAV-CRMP2 protects retinal ganglion cells and stabilizes axons and myelin after partial optic nerve injury. Exp Neurol. 2020. https:\/\/doi.org\/10.1016\/j.expneurol.2019.113167.","DOI":"10.1016\/j.expneurol.2019.113167"},{"key":"2787_CR28","doi-asserted-by":"publisher","unstructured":"Looser ZJ, Barrett MJP, Hirrlinger J, Weber B, Saab AS. Intravitreal AAV-delivery of genetically encoded sensors enabling simultaneous two-photon imaging and electrophysiology of optic nerve axons. Front Cell Neurosci. 2018. https:\/\/doi.org\/10.3389\/fncel.2018.00377.","DOI":"10.3389\/fncel.2018.00377"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02787-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-02787-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02787-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T13:14:36Z","timestamp":1657631676000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-02787-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,12]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2787"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-02787-y","relation":{},"ISSN":["1471-2377"],"issn-type":[{"type":"electronic","value":"1471-2377"}],"subject":[],"published":{"date-parts":[[2022,7,12]]},"assertion":[{"value":"28 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in compliance with the International Conference on Harmonisation, Good Clinical Practice, and applicable regulatory requirements. The protocol was reviewed by an independent and appropriately constituted institutional review board\/independent ethics committee. Informed consent was given by the patient for use of the data related to the excision for scientific research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication is included in the informed consent form signed by all patients; the patient is now deceased.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Nancy J Newman is a consultant for GenSight Biologics, Santhera Pharmaceuticals and Stealth BioTherapeutics, received research support from GenSight Biologics and Santhera Pharmaceuticals, served on the Data Safety Monitoring Board for Quark NAION study, and is a medical legal consultant. David J Calkins is a consultant for GenSight Biologics and Stuart Therapeutics. Patrick Yu-Wai-Man is a consultant for GenSight Biologics and Stealth BioTherapeutics and has received research support from GenSight Biologics and Santhera Pharmaceuticals. Valerio Carelli is a consultant for GenSight Biologics, Santhera Pharmaceuticals and Stealth BioTherapeutics and has received research support from Santhera Pharmaceuticals and Stealth BioTherapeutics. Magali Taiel is employed by GenSight Biologics, the sponsor of these studies. Fran\u00e7ois Rugiero is an employee of Diamond Pharma Services, which received payment for non-clinical consulting. Pramila Singh, Alexandra Rogue and Philippe Ancian are employees of Charles River Laboratories, Evreux, France, which received payment for the conduct of this research from GenSight Biologics. Jos\u00e9 A Sahel is a cofounder and shareholder of GenSight Biologics and the patent coauthor on allotopic transport. The other authors have no conflicts of interest to declare that are relevant to the content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"257"}}